Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have been given an average rating of “Moderate Buy” by the six research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $58.40.

Several brokerages have recently issued reports on ELVN. The Goldman Sachs Group increased their target price on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. HC Wainwright increased their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Guggenheim began coverage on Enliven Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $80.00 target price for the company.

Insider Activity

In other news, CFO Benjamin Hohl sold 10,000 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.58, for a total value of $295,800.00. Following the completion of the transaction, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. KBC Group NV bought a new position in Enliven Therapeutics during the 1st quarter valued at approximately $38,000. Mirae Asset Global Investments Co. Ltd. increased its position in Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after buying an additional 594 shares in the last quarter. BNP Paribas Financial Markets increased its position in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Enliven Therapeutics during the 4th quarter valued at approximately $83,000. Finally, Quantbot Technologies LP increased its position in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

NASDAQ ELVN opened at $39.57 on Monday. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $48.53. The stock has a 50 day simple moving average of $40.98 and a two-hundred day simple moving average of $29.67. The stock has a market cap of $2.41 billion, a P/E ratio of -23.69 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. Sell-side analysts predict that Enliven Therapeutics will post -1.59 earnings per share for the current year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.